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Background/aim: Hemophagocytic lymphohistiocytosis (HLH) is a clinical, biological, and pathological entity that is rare but has certain
morbidity that may be life-threatening. This work aims to establish a focus on the hemophagocytic lymphohistiocytosis and analyze
different aspects of diagnosis while emphasizing the biological data.
Materials and methods: We report the results of a retrospective study conducted in the hematology department of Avicenna Hospital in
Marrakesh. Thirty-one patients with hemophagocytic lymphohistiocytosis were enrolled.
Results: The clinical presentation was dominated by fever and deterioration of the general state for almost all our patients. Splenomegaly
was objectified in 90% of the patients. Hepatomegaly, lymphadenopathy, and hemorrhagic manifestations were observed in almost
50% of the patients. Biological assessments revealed bi- or pancytopenia in 96% of the patients, and coagulation disorders in 51% of
the patients. On the other hand, hyperferritinemia was found in 84% of the patients, and hepatic cytolysis and hypertriglyceridemia in
half of the patients. Hemophagocytosis was observed in all bone marrow samples taken from our patients. Concerning the evolution of
patients, in 38.5% of the patients, the evolution was favorable with regression of clinical and biological signs. Twenty six percent of the
patients had died, mainly from multiple organ failure and disseminated intravascular coagulation.
Conclusion: HLH is a diverse condition with many causes and is likely to be under-recognized, which contributes to its high morbidity
and mortality. Clinicians need to be able to recognize the signs and symptoms commonly seen in HLH and actively pursue this diagnosis
in the cases of undiagnosed febrile illness with multiorgan dysfunction. Early recognition is crucial for any reasonable attempt at curative
therapy to be made.
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1. Introduction
Hemophagocytic lymphohistiocytosis (HLH) is a
complex clinical–biological association resulting from
the inappropriate activation and proliferation of cells
from the lymphohistiocyte lineage. It is still unknown
and its diagnosis is frequently delayed in some patients
given the atypical and polymorphous presentation of its
manifestations.
It is a rare disorder, affecting both the adult and the child
whose etiologies and pathophysiological mechanisms are
multiple, which accounts for the diagnostic and therapeutic
difficulties. This work aims to establish a focus on the HLH
through these cases and to analyze the different aspects of
the diagnosis while emphasizing the biological data.
2. Patients and methods
This is a descriptive and analytical retrospective study over
a period of seven years from April 2011 to March 2018,

including about 31 cases of HLH, using the data collected
in the hematology laboratory of the Avicenna Hospital of
Marrakesh.
Thus, the diagnosis of HLH was retained in the
presence of clinical and biological signs, according to
the diagnostic criteria of Henter et al. 2007 [1]: fever,
splenomegaly, cytopenia (hemoglobin (Hb) <90 g/L,
platelets <100 × 109/L, neutrophils (PNN) <1 × 109 /L),
hypertriglyceridemia (>3 mmol/L) and/or hypofibrinemia
(<1.5 g/L), hemophagocytosis (marrow), ferritin >500
mg/L, soluble CD25 >2400 UI/mL, and natural killer
activity zero or lower.
The blood count was determined on a calibrated
and controlled “Sysmex® XT 4000” automated system,
supplemented by a May-Grünwald-Giemsa stained blood
smear, and then observed under a microscope.
The medullary punctures were performed on the
sternum next to the second intercostal space for adults,
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and the anterior superior iliac spines for children. The
smears were spread on glass slides (medullary smear),
then observed under a microscope after May-GrünwaldGiemsa staining using the manual method. For each
patient, at least two independent readings of blood and
bone marrow smears were performed and validated by the
cytologists. The hemostasis assessment was performed on
the “Stago® STA Compact” automaton and the biochemical
report on the “Cobas® 6000” automaton.
The data was collected from the medical records of
the patients. The exploitation of the data was carried out
by using the Excel© software, and the statistical analysis
using the software SPSS version 10 for Windows. The data
analyzed in this study are the epidemiological, clinical, and
biological data of this syndrome.
3. Results
The average age of the patients was 35 years with extremes
ranging from 12 to 57 years old. Of these patients, 61%
were males, which gives a sex ratio of 1.58. Five patients
had an underlying etiology, the first patient was followed
for Hodgkin lymphoma, the second one had systemic
lupus erythematosus, the third had severe combined
immunodeficiency, the fourth had juvenile idiopathic
arthritis, and the fifth had a known asthma and noninsulindependent diabetese. The delay in management was
variable with an average of 28 days, and extremes ranging
from 10 days to 2 months.
The clinical presentation of the patients was dominated
by fever and deterioration of the general state. Ninety
percent of the patients had splenomegaly. Hepatomegaly,
lymphadenopathy, and hemorrhagic manifestations were
present in almost 50% of the patients. Other clinical signs
have been found, including cutaneous and pulmonary
manifestations. The clinical presentation of our patients is
shown in Table 1.
The biological presentation of our patients was
dominated by abnormalities of the hemogram; cytopenia
was found in all patients, in the form of pancytopenia
in 67.7% of the patients and bicytopenia in 29% of the
Table 1. Clinical presentation of patients.
Symptom

Frequency

Fever

100%

Deterioration of the general state

93.5%

Splenomegaly

90.3%

Hemorrhagic manifestations

51.6%

Hepatomegaly and/or lymphadenopathy

48.4%

Skin damage

9.7%

Pulmonary impairment

3.2%

patients. Thrombocytopenia, less than 100 × 109/L, was
the most frequently observed cytopenia (96.8% of the
patients). Anemia (Hb < 90 g/dL) was indeed observed in
90.3% of the patients, it was normochromic normocytic
in 83.9% and normochromic microcytic in 6.4% of the
patients. Neutropenia was observed in 77.4% of patients,
leukocytosis in PNN in 6.4% of the patients.
In the myelogram, the marrow was rich in 71%
of the patients. All patients had signs of macrophage
activation with images of haemophagocytosis (100%),
the percentage of activated macrophages exceeded 3% in
83% of the patients. Medullary smear abnormalities were
documented in all our patients with varying frequencies,
erythroblastosis in 25.8% of the patients, monocytosis in
12.9%, and hyperplasia of the lymphoid lineage in one
patient.
A disturbance of the haemostasis assessment was
observed in 51.6% of the patients, with an extension of the
Quick Time (TQ) in 51% of the patients and the Partial
Thromboplastin time and Activator (TCA) in 48% of the
patients.
Regarding the biochemical assessment, the increase in
lactate dehydrogenases (LDH) was almost constant (87%),
as was the hyperferritinemia (84%). Triglycerides was high
in 51.6% of the patients. Hepatic cytolysis was also present
in almost half of the patients. An inflammatory syndrome
marked by increased sedimentation rate and / or reactive
protein C (CRP) was observed in 80% of the patients. The
main abnormalities of the biological assessment found are
illustrated in Table 2.
Concerning the evolution of patients, in 38,5% of
patients, the evolution was favorable with regression of
clinical and biological signs. Twenty six percent of patients
died, mainly for multiple organs failure and disseminated
intravascular coagulation. Follow up data was lost for 11 of
the patients (35,48%).
4. Discussion
HLH is a rare, serious clinical, biological, and histological
entity characterized by excessive activation of macrophages
and T cells leading to a hyperinflammatory state. It
is distinguished in primitive (related to a congenital
immunodeficiency) and secondary (related to infections,
neoplastic and autoimmune diseases).
The diagnostic criteria for HLH are those defined by
Henter et al. in 2007 [1]. These criteria include on the one
hand biological data: hematological and biochemical, and
on the other hand genetic data. The diagnosis of HLH has
evolved with the introduction, in particular, of new criteria
directly related to the physiopathology, namely the increase
of the soluble receptor levels of interleukin-2 (IL-2), sCD25,
reflection of the hyperactivation of the immunological
system, and decreased cytotoxicity functions of innate
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Table 2. The main biological anomalies observed in our series.
Biological anomaly

Percentage

Anemia (Hb < 90 g/L)

90.3%

Thrombocytopenia (PQ < 100 × 109/L)

96.8%

Neutropenia (PNN < 1 × 10 /L)

77.4%

TQ lengthened ( ratio > 1.3)

51.6%

TCA lengthened ( ratio > 1.3)

48.4%

Elevated transaminases (ALAT/ASAT > 60 UI/L)

51.6%

GGT and / or PAL high (GGT > 55 UI/L ; PAL > 200 UI/L)

32.2%

High LDH (LDH > 220 UI/L)

87.1%

Hypertriglyceridemia (TG > 3 mmol/L)

51.6%

Hyperferritinemia ( > 500 mg/L)

83.9%

Hyponatremia (Na+ < 128 mmol/L)

19.3%

High blood sugar (Gly > 7 mmol/L)

9.7%

Sedimentation rate > 25 mm and / or CRP > 6 mg/L

80.6%

9

immunity cells called Natural killer. However we did not
undertake within this study any genetic tests nor soluble
CD25 and natural killer cell activity.
Clinically, HLH is characterized by a set of important
general signs, organomegaly, and lymphadenopathy
with neurological, digestive, pulmonary signs indicating
multiorgan involvement. Its clinico-biological signs are
not very specific but their association should suggest
a diagnosis. The fever is often high. It is caused by the
high level of proinflammatory cytokines such as tumor
necrosis factor alpha (TNF-α), Macrophage Inflammatory
Protein 1 alpha (MIP-1α), interferon gamma (IFN-γ),
and IL-6 in particular [2,3]. In our series, all patients had
a fever, which is consistent with the literature data [4–6].
The enlargement of the lymphoid organs can affect the
lymph nodes, the liver, and the spleen. This organomegaly
corresponds to an infiltration by lymphocytes and
macrophages. Splenomegaly was present in 90% of the
patients in our series. On the other hand, hepatomegaly
and lymphadenopathies were found in almost half of our
patients, which partly coincides with the results of Rivière
et al.’s study [7].
In terms of biological abnormalities, hematological
involvement was by far the most common. The cardinal
sign of this attack is the presence of cytopenias secondary to
phagocytosis of the hematopoietic elements [8]. Cytopenias
are almost constant in the different series studied, in 89.4%
of the patients in Larroche’s study [9] and in 99% of the
patients in Li et al.’s study [10]. In agreement with the
literature data, the biological sign found in the foreground
of our study was cytopenias (100%); pancytopenia
and bicytopenia were found in 67.7% and 29% of the

1334

patients, respectively. The mechanism of these cytopenias
is both central and peripheral, explaining the little or
no regenerative nature of anemia despite its hemolytic
component. Hemophagocytosis plays a quantitative role
that may not be important in these cytopenias which are
more related to the secretion of TNF-α as well as IFN-γ
[11].
Moreover, anemia has been reported in 90.3% of our
observations, which is consistent with the results of several
series of the literature [4,12]. It is found in 80% to 100% of
the patients, it is often normocytic, normochromic, and
aregenerative [6]. Thrombocytopenia is almost constant,
found in more than 86% of the patients, often less than
100 × 109/L [6,13]. Thrombocytopenia was observed in
96.8% of our patients. Its mechanism is central, but also
sometimes peripheral, notably through disseminated
intravascular coagulation, which complicates transfusion
management [6]. Leukopenia, appearing in 60% of the
patients, is rather late. It is marked by lymphopenia and
sometimes by profound neutropenia [6]. It was revealed in
77.4% of the patients in our series.
In myelogram, the typical cytological appearance
of HLH is that of histiocytic and / or macrophage
proliferation with images of hemophagocytosis [8]. This
hemophagocytosis is important to the diagnosis of HLH,
but it is not mandatory. Signs of hemophagocytosis are
sought on the myelogram, but less frequently on lymph
node biopsies or splenectomy specimens [11].
The increase of ferritin above 500 mg/L is part of
HLH’s diagnostic criteria. It was observed in 83.9% of our
patients. Hyperferritinemia is an indicator of macrophage
activation and can reflect hyperproduction of TNF‐α,
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indeed, most cases of hyperferritinemia are not caused by
transfusional iron overload, but by the hyperproduction of
TNF‐α. Moreover, although the serum ferritin cut‐off in
the HLH‐2004 diagnostic criteria is ≥500 ng/mL, it often
rises to more than several thousand ng/mL in patients
with HLH [14].
Hypertriglyceridemia, which is not associated with
increased cholesterol, seen in 51.6% of our patients, is part
of the HLH picture and can itself be a cause of pancreatitis.
This is due to the action of TNF‐α and Il-1 released by
activated macrophages and inhibiting lipoprotein lipase.
It is usual to observe liver abnormalities with elevated
aminotransferases, alkaline phosphatases, bilirubin, and
a moderate decrease in factor V, which indicates some
degree of hepatic failure [11].

In conclusion, the HLH is a rapidly progressive, lifethreatening syndrome of excessive immune activation.
It is associated with high mortality rate. Making the
diagnosis of HLH could be quite challenging due to
the broad range of presenting symptoms and their
lack of specificity. Common findings include fever,
hepatosplenomegaly, rash, lymphadenopathy, neurologic
symptoms, cytopenias, high serum ferritin, and liver
function abnormalities. Etiologically, secondary HLH,
especially of infectious origins, remains the most frequent.
Awareness of the clinical symptoms and of the diagnostic
criteria of HLH is important to start life-saving therapy
with immunosuppressive/immunomodulatory agents in
time.
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